Edesa Biotech, Inc.·4/A

Jan 13, 8:30 AM ET

Sistilli Carlo 4/A

4/A · Edesa Biotech, Inc. · Filed Jan 13, 2020

Insider Transaction Report

Form 4/AAmended
Period: 2020-01-08
Transactions
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+1,8271,827 total(indirect: Held by York-Cav Enterprises, Inc.)
    Exercise: $4.80From: 2020-07-08Exp: 2023-07-08Common Shares (1,827 underlying)
  • Award

    Common Shares

    2020-01-08$4.11/sh+2,436$10,0122,436 total(indirect: Held by York-Cav Enterprises, Inc.)
  • Award

    Common Share Warrants (Right to Buy)

    2020-01-08+1,2181,218 total(indirect: Held by York-Cav Enterprises, Inc.)
    Exercise: $4.00From: 2020-07-08Exp: 2020-11-08Common Shares (1,218 underlying)
Footnotes (5)
  • [F1]The reported securities are included within 2,436 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share.
  • [F2]York-Cav Enterprises, Inc. is partially owned by the reporting party.Mr. Sistilli disclaims beneficial ownership except to the extent of his precautionary interest therein.
  • [F3]Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023.
  • [F4]Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020.
  • [F5]Amended to reflect acquisition from the issuer.

Documents

1 file
  • 4
    section16.xml

    PRIMARY DOCUMENT